GLSI

Greenwich LifeSciences, Inc.

15.94 USD

Last updated Sep 4, 20:15 UTC

Yesterday HIGH

$16.02

Yesterday LOW

$15.5

52w HIGH

$34.1

52w LOW

$7.78

EPS

-0.27

PE

-59.04

Next Earnings

Nov 13, 2026

Overview News Government Trades Fundamentals

Greenwich LifeSciences, Inc. stock is up 10.77% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 6 September’s closed higher than August.

Benzinga Newsdesk

Tue Jun 2, 2026

Greenwich LifeSciences shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Benzinga Newsdesk

Mon Jun 1, 2026

Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate

Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.31) by 87.1 percent. This is a 4.92 percent increase over losses of $(0.61) per share
Benzinga Newsdesk

Mon Jun 1, 2026

Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026

from the ASCO Annual Meeting 2026.The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website here.This is the
Benzinga Newsdesk

Mon Jun 1, 2026

Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga Newsdesk

Fri May 22, 2026

Greenwich LifeSciences Receives Nasdaq Noncompliance Notice

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated
Benzinga Newsdesk

Wed Apr 22, 2026

Greenwich LifeSciences Receives Nasdaq Notice Regarding Late Form 10-K Filing
Avi Kapoor

Wed Apr 22, 2026

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.
Benzinga Newsdesk

Mon Apr 20, 2026

Greenwich LifeSciences Reports 70%–80% Drop In Cancer Recurrence In Early Trial Data

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga Newsdesk

Tue Apr 14, 2026

Greenwich Lifesciences Used Its ATM Facility To Issue Shares Directly Into The Market At Prevailing Prices. Proceeds Raised In Q1 2026 Exceeded The Quarter's Cash Burn, Resulting In An Estimated Cash Balance Of About $10.5M As Of March 31
Benzinga Newsdesk

Tue Apr 7, 2026

Greenwich LifeSciences Says Breast Cancer Therapy Could Double Patient Reach With New Patent Claims

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an